BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 270 filers reported holding BIO-TECHNE CORP in Q1 2017. The put-call ratio across all filers is 0.76 and the average weighting 0.1%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2019 | $17,648,000 | +15.4% | 88,885 | -15.9% | 0.01% | 0.0% |
Q4 2018 | $15,296,000 | -67.3% | 105,694 | -53.9% | 0.01% | -20.0% |
Q3 2018 | $46,824,000 | +179.8% | 229,404 | +102.8% | 0.02% | +36.4% |
Q2 2018 | $16,733,000 | -9.1% | 113,096 | -7.2% | 0.01% | -8.3% |
Q1 2018 | $18,410,000 | +21.0% | 121,888 | +3.8% | 0.01% | +20.0% |
Q4 2017 | $15,209,000 | +6.5% | 117,395 | -0.6% | 0.01% | 0.0% |
Q3 2017 | $14,285,000 | -3.2% | 118,162 | -5.9% | 0.01% | 0.0% |
Q2 2017 | $14,753,000 | +13.3% | 125,556 | -2.0% | 0.01% | +11.1% |
Q1 2017 | $13,026,000 | -22.9% | 128,141 | -22.0% | 0.01% | -30.8% |
Q4 2016 | $16,899,000 | -28.4% | 164,341 | -23.7% | 0.01% | -13.3% |
Q3 2016 | $23,590,000 | +38.8% | 215,434 | +43.0% | 0.02% | +15.4% |
Q2 2016 | $16,993,000 | +40.5% | 150,691 | +17.8% | 0.01% | +44.4% |
Q1 2016 | $12,094,000 | -5.6% | 127,949 | -10.1% | 0.01% | -10.0% |
Q4 2015 | $12,812,000 | -2.7% | 142,361 | 0.0% | 0.01% | 0.0% |
Q3 2015 | $13,163,000 | +1.3% | 142,361 | +7.8% | 0.01% | +11.1% |
Q2 2015 | $13,000,000 | -3.1% | 132,023 | -1.3% | 0.01% | 0.0% |
Q1 2015 | $13,412,000 | +3.8% | 133,737 | -4.4% | 0.01% | 0.0% |
Q4 2014 | $12,927,000 | – | 139,903 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
Westwind Capital | 27,946 | $9,687,000 | 3.17% |
MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |